Patents Assigned to Repurposed Therapeutics, Inc.
  • Emesis treatment
    Patent number: 10646457
    Abstract: A composition for the treatment of emesis comprising 8-hydroxy-2-(dipropylamino)tetralin in which the ratio of the S enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin to the R enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin is between 2:1 and 10:1, and a method of treating or preventing emesis with such a composition.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: May 12, 2020
    Assignee: REPURPOSED THERAPEUTICS, INC
    Inventors: David Helton, James Lucot
  • Emesis treatment
    Patent number: 10206889
    Abstract: A composition for the treatment of emesis comprising 8-hydroxy-2-(dipropylamino)tetralin in which the ratio of the S enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin to the R enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin is between 2:1 and 10:1, and a method of treating or preventing emesis with such a composition.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: February 19, 2019
    Assignee: REPURPOSED THERAPEUTICS, INC.
    Inventors: David Helton, James Lucot
  • Emesis treatment
    Patent number: 9918949
    Abstract: A method of treating or preventing emesis through the administration of an effective dosage of a 2-(amino)tetralin compound in which one of the S or R enantiomers of the 2-(amino) tetralin compound is present in the composition in excess of the other enantiomer, and compositions comprising such a 2-(amino)tetralin compound in which the ratio of the S and R enantiomers is at least 2:1.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: March 20, 2018
    Assignee: Repurposed Therapeutics, Inc.
    Inventors: David Helton, James Lucot